newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

  • Ascentage Pharma presented oral report results for Lisaftoclax monotherapy at the 67th ASH Annual Meeting on December 6, 2025, highlighting data from a registrational Phase II study in China.
  • The study included 77 heavily pretreated patients with BTK-refractory relapsed/refractory CLL/SLL, featuring a high proportion of high-risk factors including 42.9% complex karyotype, 39% del(17p)/TP53 mutation, and 53.2% unmutated IGHV.
  • Among 72 evaluable patients, Lisaftoclax demonstrated an objective response rate (ORR) of 62.5% with a median progression-free survival of 23.89 months.
  • Deep responses were observed with 21.8% of patients achieving minimal residual disease (MRD) negativity in peripheral blood and 54.5% of bone marrow evaluable patients achieving MRD negativity.
  • The drug showed a manageable safety profile with frequent grade ≥3 hematologic toxicities but no reported tumor lysis syndrome (TLS) or treatment-related deaths.
  • These clinical results supported the National Medical Products Administration (NMPA) approval of Lisaftoclax in China in July 2025 for adults with CLL/SLL who have received prior systemic therapy including BTK inhibitors.
  • Lisaftoclax is an orally administered Bcl-2 selective inhibitor currently under investigation in four global Phase III trials for CLL/SLL, acute myeloid leukemia, and myelodysplastic syndrome.